Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

RGS2 modulates the activity and internalization of dopamine D2 receptors in neuroblastoma N2A cells.

Luessen DJ, Hinshaw TP, Sun H, Howlett AC, Marrs G, McCool BA, Chen R.

Neuropharmacology. 2016 Nov;110(Pt A):297-307. doi: 10.1016/j.neuropharm.2016.08.009. Epub 2016 Aug 12.

2.

Adenosine Receptors Differentially Regulate the Expression of Regulators of G-Protein Signalling (RGS) 2, 3 and 4 in Astrocyte-Like Cells.

Eusemann TN, Willmroth F, Fiebich B, Biber K, van Calker D.

PLoS One. 2015 Aug 11;10(8):e0134934. doi: 10.1371/journal.pone.0134934. eCollection 2015.

3.

[Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency].

Gareeva AE, Zakirov DF, Valinurov RG, Khusnutdinova EK.

Mol Biol (Mosk). 2013 Nov-Dec;47(6):934-41. Russian.

4.

Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study.

Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN.

PLoS One. 2012;7(5):e36561. doi: 10.1371/journal.pone.0036561. Epub 2012 May 15.

5.

Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model.

Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, Lerer B.

Eur Neuropsychopharmacol. 2012 May;22(5):379-86. doi: 10.1016/j.euroneuro.2011.09.006. Epub 2011 Oct 6.

PMID:
21982117
6.

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms.

Le-Niculescu H, Balaraman Y, Patel SD, Ayalew M, Gupta J, Kuczenski R, Shekhar A, Schork N, Geyer MA, Niculescu AB.

Transl Psychiatry. 2011 May 24;1:e9. doi: 10.1038/tp.2011.9.

7.

Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP).

Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, Sakai Y, Suzuki T, Arai H.

Neurosci Lett. 2010 Jan 18;469(1):55-9. doi: 10.1016/j.neulet.2009.11.043. Epub 2009 Nov 24.

PMID:
19931593
8.

cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour.

Kleppisch T, Feil R.

Handb Exp Pharmacol. 2009;(191):549-79. doi: 10.1007/978-3-540-68964-5_24. Review.

PMID:
19089345
9.

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region.

Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B.

Pharmacogenomics J. 2009 Apr;9(2):103-10. doi: 10.1038/tpj.2008.6. Epub 2008 Mar 18.

PMID:
18347610
10.

Association of RGS2 and RGS5 variants with schizophrenia symptom severity.

Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF.

Schizophr Res. 2008 Apr;101(1-3):67-75. doi: 10.1016/j.schres.2008.01.006. Epub 2008 Feb 11.

11.

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.

Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, Katz E, Kotler M, Olender T, Deshpande SN, Lancet D, Ben-Asher E, Lerer B.

Pharmacogenet Genomics. 2007 Jul;17(7):519-28.

PMID:
17558307
12.
13.

Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique.

Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, Pearce DA, Singh S, Siderovski DP, Willard FS, Fukuda M.

Neuropsychopharmacology. 2006 Sep;31(9):1888-99. Epub 2006 Jan 11.

Supplemental Content

Loading ...
Support Center